Compare Abeona Therapeutics Inc (ABEO) vs Global X MSCI Argentina ETF (ARGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X MSCI Argentina ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Global X MSCI Argentina ETF trades at $92.84. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X MSCI Argentina ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | ARGT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $102.94 |
52-Week Low | $4.17 | $67.55 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARGT trades at $93.99, up 2.78% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock is near resistance at $94, with support at $90. Recent news highlights institutional interest from Stanley Druckenmiller and analyst upgrades citing Argentina's economic reforms and potential valuation upside.
Outlook remains mixed; bullish sentiment from analysts points to a 28% upside if Argentina's turnaround continues, but risks include political volatility and concentrated holdings. The stock offers speculative growth potential amid high macroeconomic uncertainty, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →
